Taysha Gene Therapies (TSHA) Competitors $2.65 +0.06 (+2.32%) Closing price 04:00 PM EasternExtended Trading$2.66 +0.00 (+0.19%) As of 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TSHA vs. HHH, KNSA, TWST, CNTA, BEAM, CGON, DNLI, HRMY, IRON, and MESOShould you be buying Taysha Gene Therapies stock or one of its competitors? The main competitors of Taysha Gene Therapies include Howard Hughes (HHH), Kiniksa Pharmaceuticals International (KNSA), Twist Bioscience (TWST), Centessa Pharmaceuticals (CNTA), Beam Therapeutics (BEAM), CG Oncology (CGON), Denali Therapeutics (DNLI), Harmony Biosciences (HRMY), Disc Medicine (IRON), and Mesoblast (MESO). Taysha Gene Therapies vs. Its Competitors Howard Hughes Kiniksa Pharmaceuticals International Twist Bioscience Centessa Pharmaceuticals Beam Therapeutics CG Oncology Denali Therapeutics Harmony Biosciences Disc Medicine Mesoblast Taysha Gene Therapies (NASDAQ:TSHA) and Howard Hughes (NYSE:HHH) are related companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends. Do analysts recommend TSHA or HHH? Taysha Gene Therapies currently has a consensus price target of $8.17, indicating a potential upside of 208.18%. Howard Hughes has a consensus price target of $80.33, indicating a potential upside of 15.15%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, equities research analysts clearly believe Taysha Gene Therapies is more favorable than Howard Hughes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Taysha Gene Therapies 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Howard Hughes 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do insiders & institutionals believe in TSHA or HHH? 77.7% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 93.8% of Howard Hughes shares are owned by institutional investors. 3.8% of Taysha Gene Therapies shares are owned by company insiders. Comparatively, 33.0% of Howard Hughes shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk and volatility, TSHA or HHH? Taysha Gene Therapies has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, Howard Hughes has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. Is TSHA or HHH more profitable? Howard Hughes has a net margin of 14.27% compared to Taysha Gene Therapies' net margin of -1,201.08%. Howard Hughes' return on equity of 10.21% beat Taysha Gene Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Taysha Gene Therapies-1,201.08% -104.93% -50.09% Howard Hughes 14.27%10.21%3.08% Does the media favor TSHA or HHH? In the previous week, Howard Hughes had 3 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 4 mentions for Howard Hughes and 1 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 1.87 beat Howard Hughes' score of 1.69 indicating that Taysha Gene Therapies is being referred to more favorably in the media. Company Overall Sentiment Taysha Gene Therapies Very Positive Howard Hughes Very Positive Which has better valuation and earnings, TSHA or HHH? Howard Hughes has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Howard Hughes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTaysha Gene Therapies$8.33M68.29-$89.30M-$0.34-7.79Howard Hughes$1.75B2.01$200.55M$5.2113.39 SummaryHoward Hughes beats Taysha Gene Therapies on 11 of the 16 factors compared between the two stocks. Get Taysha Gene Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TSHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TSHA vs. The Competition Export to ExcelMetricTaysha Gene TherapiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$555.97M$3.87B$5.70B$9.51BDividend YieldN/A1.17%4.69%4.01%P/E Ratio-7.794.4621.1920.14Price / Sales68.2911.99461.30104.37Price / CashN/A6.4836.2258.56Price / Book7.572.798.665.87Net Income-$89.30M-$109.62M$3.25B$258.55M7 Day Performance3.11%5.55%4.20%2.23%1 Month Performance8.61%11.53%10.82%12.76%1 Year Performance16.74%23.43%34.70%19.36% Taysha Gene Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TSHATaysha Gene Therapies4.2565 of 5 stars$2.65+2.3%$8.17+208.2%+15.6%$555.97M$8.33M-7.79180Positive NewsHHHHoward Hughes2.9072 of 5 stars$68.93+0.2%$80.33+16.5%+1.1%$3.46B$1.75B11.79608Positive NewsKNSAKiniksa Pharmaceuticals International3.4621 of 5 stars$28.42-2.1%$39.33+38.4%+6.7%$2.12B$423.24M-113.68220News CoverageTWSTTwist Bioscience4.3708 of 5 stars$34.77-1.1%$50.40+45.0%-37.4%$2.11B$312.97M-10.70990Positive NewsCNTACentessa Pharmaceuticals3.3263 of 5 stars$16.06+2.4%$28.10+75.0%+51.2%$2.10B$6.85M-8.87200Insider TradeBEAMBeam Therapeutics2.2257 of 5 stars$21.03+1.3%$48.75+131.8%-29.7%$2.09B$63.52M-4.56510Analyst RevisionCGONCG Oncology2.2411 of 5 stars$26.90+0.6%$55.30+105.6%-21.3%$2.04B$1.14M0.0061DNLIDenali Therapeutics4.2668 of 5 stars$13.83-1.2%$33.71+143.8%-39.4%$2.03B$330.53M-5.18430News CoverageUpcoming EarningsHRMYHarmony Biosciences4.7998 of 5 stars$35.25+0.1%$51.00+44.7%+11.9%$2.02B$714.73M13.45200Positive NewsAnalyst RevisionIRONDisc Medicine3.3645 of 5 stars$59.38+2.8%$95.73+61.2%+36.0%$2.00BN/A-15.1530MESOMesoblast1.4489 of 5 stars$14.65-6.2%$18.00+22.9%+113.6%$2.00B$5.90M0.0080Upcoming EarningsGap Down Related Companies and Tools Related Companies HHH Alternatives KNSA Alternatives TWST Alternatives CNTA Alternatives BEAM Alternatives CGON Alternatives DNLI Alternatives HRMY Alternatives IRON Alternatives MESO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TSHA) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Taysha Gene Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Taysha Gene Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
